SINOMED | Coronary Stents

China’s First Cardiac Drug-eluting Stent Entering European and American markets

SINOMED Science and Technology Co., Ltd. is an international company rooted in China, focused on the research and development, production, and sales of high-end interventional medical devices for the global market. The company was founded in 2007 in the Tianjin Economic and Technological Development Area, with a registered capital of 413.456 million RMB. SINOMED has subsidiaries in Beijing, Suzhou, Hong Kong, the United States, Japan, and France. In October 2019, the company was listed on the Shanghai Stock Exchange and became a listed company on the STAR Market.

After more than a decade of development, SINOMED has established an internationally recognized R&D, production, and operation system. The company’s business covers key areas of interventional treatments for cardiovascular, cerebrovascular, and structural heart diseases. SINOMED continues to focus on product innovation and has developed 8 key technologies, with 24 products in the market. Its main products include coronary drug-eluting stents, coronary balloons, intracranial rapid exchange balloons, intracranial drug-eluting stents, and more. These products have been used in over 2 million procedures and are available in more than 2,000 hospitals. The company holds over 200 patents globally, covering China, the United States, Europe, and other regions. SINOMED has also undertaken 7 national and provincial-level research projects, including key research topics from the "13th Five-Year Plan" for National Key R&D Programs.

SINOMED has been recognized as a National-level Specialized and Innovative “Little Giant” Enterprise and Tianjin Municipal-level Specialized and Innovative “Little Giant” Enterprise, and has been designated as the Tianjin Medical Device Inspector Training Base, etc. It has been approved as a Tianjin Enterprise Technology Center, a Manufacturing Single Champion Enterprise, and a National Intellectual Property Advantage Enterprise. The company’s products have won the Tianjin Patent Gold Award and the First Prize in the Tianjin Intellectual Property Innovation and Entrepreneurship Invention & Design Competition. It was also included in the 2021 Important Medical Advances in China.

HT Supreme Coronary Stent

The HT Supreme drug-eluting stent is China’s first coronary stent product to undergo pre-market clinical trials simultaneously in China, the United States, Japan, and Europe, and apply for product patents in these regions. The product received CE certification from the European Union in December 2019 and was approved in China in December 2020. It was subsequently approved in Thailand, Singapore, Indonesia, Turkey, and Taiwan in 2022 and 2023. The HT series of next-generation stents has been selected for national procurement and has been chosen by more than 1,000 hospitals nationwide.